Rosetta Genomics Posts Higher R&D Costs, Widened Loss in Q2; Inks Co-Development Pact with Ben Gurion University | GenomeWeb
NEW YORK (GenomeWeb News) - Rosetta Genomics today reported no second-quarter revenues, accompanied by a 55 percent rise in R&D spending and a 27 percent increase in net loss.
 
R&D spending for the three months ended June 30 increased to $1.7 million from $1.1 million in the year-ago period.
 
Net loss increased to $2.3 million from $1.8 million in the second quarter of 2005.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.